Product Description
Mechanisms of Action: Akt Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Uterine Cancer|Cervical Cancer|Multiple Myeloma|Melanoma|Acute Myeloid Leukemia|Triple Negative Breast Cancer
Phase 1: Triple Negative Breast Cancer|Endometrial Cancer|Melanoma|Ovarian Cancer|Lymphoma|Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2013-02148 | P2 |
Completed |
Multiple Myeloma |
2019-08-31 |
|
| NCI-2013-01320 | P2 |
Active, not recruiting |
Melanoma |
2018-05-16 |
|
| NCT01958112 | P2 |
Terminated |
Uterine Cancer|Cervical Cancer |
2017-11-01 |
|
| NCI-2013-01895 | P2 |
Completed |
Triple Negative Breast Cancer |
2017-01-20 |